Asset
VS-5584
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02372227 | phase1 | terminated | 2015-01-01 | 2015-10-01 | Verastem, Inc. | A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma |
| NCT01991938 | phase1 | terminated | 2013-11-01 | 2016-12-01 | Verastem, Inc. | Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma |
FDA applications (0)
This company has no applications containing this asset.